SMi Group's Superbugs & Superdrugs 2016 conference returns to London for its 18th year next March

1. Key Business Benefits to Attend:
• Network with industry-leading experts on drug and antimicrobial
material developments
• Learn new funding opportunities from BARDA and US National
plans, to combat antimicrobial resistance
• Understand how the EU Commission's practical approach in R&D
can support your business growth
• Reinvigorate business models with Project DRIVE-AB and find
workable solutions to strengthen drug development
• Strengthen your antibiotic pipeline with new insights on microbiome
profiling to fight multi-resistant gram negative infections
• Hear important discussions on tackling major bottlenecks that hinder
development of new antimicrobial drugs with our star panel line-up
SMi present the 18th annual conference...
16 - 17
MAR
2016Holiday Inn Kensington Forum, London, UK
Superbugs &
Superdrugs
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK
www.superbugssuperdrugs.com
Register online or fax your booking form to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
Pushing financial and collaborative incentives to accelerate clinical success
@SMIPHARM
WORKSHOP A
Rapid Diagnostic Tools for Infectious Diseases
Workshop Leader:
Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd
8.30am - 12.30pm
WORKSHOP B
Making a Material Difference to Healthcare
Workshop Leader:
Andrew Cross, Director, ACT Surfaces Ltd
1.30pm - 5.30pm
Chairs for 2016:
Richard Bax, Lloyd Czaplewski,
Senior Partner, Director,
Transcrip Partners Chemical Biology Ventures Ltd
Elite International Speakers Include:
• Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases
and Advancing Public Health, European Commission
• Melissa Stundick, Chief, Anti-Infectives Programme, BARDA
• Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents
• Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals
• Ankit Mahadevia, MD , President & CEO, Spero Therapeutics
• Eszter Nagy, Co-founder, President and CSO, Arsanis
• Jean de Gunzburg, Chief Scientific Officer, Da Volterra
• David Cook, Chief Scientific Officer, Blueberry Therapeutics
• Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience Ltd
• Steven Boakes, Associate Director of Microbiology, Cantab
Anti-Infectives
BOOK BY 30TH NOVEMBER AND SAVE £400
BOOK BY 18TH DECEMBER AND SAVE £200
BOOK BY 29TH JANUARY AND SAVE £100

2. Register online at: www.sup
Dear Colleagues
It is with great pleasure that we welcome you to participate in the 18th Annual Superbugs & Superdrugs conference taking place on
16th -17th March 2016, Central London, UK.
Antimicrobial resistance is clearly a serious global threat. To combat potential epidemic, requires both industry and government
collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response. As new
resistance mechanisms rapidly spread throughout the developed and developing nations, this is putting our existing antibiotic pipeline
under greater higher risk of failing to resolve many standard medical treatments, as well as compromising our achievements in modern
standard medicine including cancer therapeutics and surgery. To curb an uncontrollable outbreak ‘storm’, we urge committed action
and international stewardship from the industry to drive anti-superbugs and superdrug developments.
We are delighted to chair this annual industry meeting in 2016 again, which will gather a high level of international experts and project
decision makers in a timely opportunity to discuss ongoing challenges and lay the foundation for innovations that will enhance the
security and R&D projects for novel therapies in anti-infectives.
Please take time to peruse the conference agenda which has been drafted with great care to give you the very best opportunity to
benchmark and learn from subject matter experts in infectious diseases, health economics and advanced technologies and solutions.
Networking and learning with our peers is the secret to improving the drug development pipeline. With practical case studies and
interactive roundtables, there is confidence that we will be able to crack the ‘chicken or the egg’ problem.
Yours Sincerely,
Richard Bax, Senior Partner, Transcrip Partners Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd
Workshop Overview:
This workshop will show attendees how complex
diagnostics can be delivered in minutes for a few
dollars in any setting across the globe using portable
devices. We will also evaluate key definitive factors
of disease diagnosis & drug resistance testing and
mobile data connection.
Why you should attend:
• Gain valuable practise of understanding what
factors to work with and look out
for in diagnosing infections and resistant strains
• Understand the dangers of misdiagnosis and the
fine lines between familiar strains and symptoms
• Learn how our models can circumvent HAI’s and
perform in disease management and drug
resistance monitoring through geo-stamped data
About the workshop leader:
Sam is chief operating officer of
QuantuMDx Group Ltd and the inventor
of underlying DNA extraction chemistries
currently being commercialised by the
company. With 14 years biotech
experience including, development of
cardiovascular medical devices, polymer drug
systems, coating technologies, industrial research
and managing a large portfolio of academic-
industry biotech collaborations. Sam has a history of
commercialising basic research, licensing and
technology transfer from SME’s and MNC’s.
Currently he oversees operations in the UK, USA and
Singapore.
About the Organisation:
QuantuMDx is passionate
about playing a role in
addressing humanitarian
health challenges and strongly believes that quality
molecular diagnostics is an innate human right and
as such should be provided to every man, woman
and child on this planet, regardless of race, country
or creed.
Our mission is to develop Q-POC™ our novel
handheld device to provide access to gold
standard molecular diagnostic testing, in minutes, to
the billions of people in poorer nations who urgently
need a rapid, cheap and accurate way of
diagnosing disease and drug resistance. This will help
address the humanitarian health challenges such as
malaria, TB, HIV and cancer and, in time, support the
eradication of some diseases by prescribing the right
drug, first time. Furthermore, we will develop Q-
POC™ to meet the strict regulatory requirements
that will enable it to become the diagnostic device
of choice for all health professionals, police, rapid
responders, vets and farmers.
Workshop Overview:
How can copper touch surfaces improve patient
outcomes and provider finances? Is this a viable
propositionforhealthcaretoday?Whycopper-how
does copper differ from other antimicrobial
surfaces? What research backs its use? Which items
to consider? What products and materials are
available?
Drawingonfeedbackandexperiencefromprevious
installations, as well as current guidelines, this
workshop will examines the evidence, cost-payback
and practical implementation concerning the
strategic deployment of copper touch surfaces.
Why you should attend:
Healthcare is under pressure to innovate, improve
patient outcomes and reduce costs. This workshop
explores a simple and low-risk intervention, and its
potential impact on HCAI rates and Antimicrobial
Resistance.
About the workshop leader:
Andrew offers a mixture of technical,
practical and commercial experience,
and works closely with engineers,
architects / designers, construction
professionals, healthcare scientists and clinical teams
to prompt a reevaluation of materials used in
healthcare settings.
About the Organisation:
Working in close partnership with
approved suppliers and healthcare
professionals,ACTSurfacesprovidea
comprehensive“endtoend”service
of advice and products. Strategic use of
Antimicrobial Copper Touch Surfaces enables
healthcare
providers to improve patient outcomes and optimise
payback.Thegoalistohelphealthcareprofessionals
select the right products and materials for their
particular setting and infection control needs.
TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK
Programme
8.30 Registration
9.00 Opening remarks and introductions
9.10 Session 1: Diagnostics
• Tracking emerging infections and outbreaks:
Current pitfalls and areas to address
• State-of-the-art diagnostic tools: What to
measure and translate
9.50 Session 2: Rapid detection techniques
• Multiple markers in accurately diagnosing
disease from broad symptoms
• The definitive factors of diagnosing disease
10.30 Afternoon Tea
11.00 Session 3: Mobile applications for different
environments
• Diagnosing in different settings: Case study
and evaluation
• Data access and transfer
11.40 Session 4: Future work and progress
• Challenges of diagnosis: mutation factors
and strain differentiation
• Discussion
12.20 Closing remarks
12.30 Close of workshop
Making a material difference to Healthcare
1.30pm – 5.30pm Workshop Leader: Andrew Cross, Director, ACT Surfaces Ltd
Programme
1.30 Registration
2.00 Opening remarks and introductions
2.10 Session 1:
• Two major issues in healthcare today
- HCAIs and AMR
2.50 Session 2:
• The role of the patient environment in
acquisition of infection and spread of AMR
3.30 Afternoon Tea
4.00 Session 3:
• Evaluating Antimicrobial efficacy for touch surfaces
• The evidence for copper
4.40 Session 4:
• Cost vs Benefit - the YHEC research
• Q&A session, practial demonstration
5.20 Closing remarks
5.30 Close of workshop
Rapid Diagnostic Tools for Infectious Diseases
8.30am – 12.30pm Workshop Leader: Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd

3. Superbugs & Superdrugs
Day One | Wednesday 16th March 2016
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Richard Bax, Senior Partner, Transcrip Partners
Models for Successful Partnerships and Clinical Management
9.10 OPENING ADDRESS: Current status and future prospects
•Progress in R&D and drug regulation
•What is happening in big Pharma
•New economic models
•What needs to be done now
Richard Bax, Senior Partner, Transcrip Partners
9.50 Extending portfolio partnerships to strengthen the antibiotic
pipeline
•Ongoing and future research and development
partnerships
•BARDA’s efforts to address goals in the U.S. National Plan to
Combat Antibiotic Resistant infections
•Establishing a biopharmaceutical incubator to meet short
and long term goals
•BARDA funding opportunities
Melissa Stundick, Chief, Anti-Infectives Programme, BARDA
10.30 Morning Coffee
10.50 Developing an antibiotic with potential for use in multiple
therapeutic indications
•Case study: Stage 3 clinical update outcomes and
response
•International collaboration for successful worldwide
commercialisation
Prabhavathi Fernandes, President & CEO,
Cempra Pharmaceuticals
11.30 Making a material difference to healthcare
•Two issues: HCAIs and AMR
•The role of touch surfaces in the acquisition of infection
and spread of AMR
•Evaluation of antimicrobial efficacy
•Evidence for copper touch surfaces and YHEC payback
model
Andrew Cross, Director, ACT Surfaces Ltd
12.10 Networking Lunch
1.10 KEYNOTE ADDRESS: Fighting global epidemics and
progressing public- private partnerships
•State of play of the EU action plan on AMR
•How is R&D being supported in a practical sense?
Line Matthiessen, MD PhD, Head of Unit Fighting Infectious
Diseases and Advancing Public Health, European
Commission
1.50 Project DRIVE-AB: New partners and developments
•Prioritising problem areas and future development
•New models and action plans
•Clinical practice strategies to aid the development pipeline
Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents
Progressive R&D and Clinical Trials
2.50 New insights of pathogen – host interactions and EU project -
INFECT
•Systems medicine approach to understand pathogenic
mechanisms
•New in vitro models to understand drug resistance at the
tissue site of infection
•Accelerating drug development and diagnostic tools
through INFECT
Anna Norrby-Teglund, Professor, Head of Center for
Infectious Medicine, Karolinska Institutet
3.30 Afternoon Tea
4.00 Monoclonal antibody-based approaches to fight severe
bacterial infections
•New paradigm to prevent and treat severe
Staphyloccocus aureus infections
•mAb products targeting MDR Gram negative infections
•Companion diagnostics for introduction of targeted
therapies and support MDR infectious disease control
Eszter Nagy, Co-founder, President and CSO, Arsanis
4.40 Application of whole genome sequencing to public health
•Whole genome sequencing as a gold standard approach
for molecular strain typing
•Outbreak investigations using whole genome sequencing
•Case study: Pattern/ type assignment
•Future perspectives in public health
Georgia Kapatai, Bioinformatician, Public Health England
5.20 Rapid diagnostic tools
•Advances in molecular diagnostic devices: Sample
preparation and PCR
•Case study: Rapid diagnosis of drug-resistant forms of TB
•Optimising speed and accuracy for rapid detection
•Sample to result processes – fluidics and microfluidics
Sam Whitehouse, Chief Operating Officer,
QuantuMDx Group Ltd
6.00 PANEL DISCUSSION: Tackling the major bottlenecks
that hinder development of new antibacterial drugs
•Sample preparation, bottle necks in work flows
•True point of care – field based (not laboratory) testing
•Multifaceted infection control programmes and cost efficiency
•Is the biotech sector the forgotten partner in developing
new treatments for AMR?
•Regulatory environment for non-traditional therapies: Is a
new paradigm needed?
•Racing “The Red Queen”: How can we win the arms race?
•Is giving taxpayer money to pharmaceutical companies
the best way of stimulating the development of new anti-
infectives?
Panel leader: Richard Bax, Senior Partner, Transcrip Partners
Panelists:
Prabhavathi Fernandes, President & CEO, Cempra
Pharmaceuticals
Eszter Nagy, Co-founder, President and CSO, Arsanis
Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd
Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience
David Cook, Chief Scientific Officer, Blueberry Therapeutics
Jean de Gunzburg, Chief Scientific Officer, Da Volterra
6.40 Chairman's Closing Remarks and Close of Day One
perbugssuperdrugs.com • Alternatively fax your registration to +44 (0)870 9090 712

4. Superbugs & Superdrugs
Day Two | Thursday 17th March 2016
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd
Strengthening the Antibiotic Pipeline
9.10 OPENING ADDRESS: What if there are no new antibiotics?
•Highlights of a review into the alternatives to antibiotics
•What can we expect within the next 10 years and how
much will it cost?
•Why antimicrobial resistance must become a BIG science
Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd
9.50 Fighting multi-resistant gram-negative infections
•Development of NCE’s and combination methods that
successfully penetrate the outer bacterial membrane
•Strategic collaborations that have strengthened product
pipeline
•HTS and characterization of MvfR inhibitors and correlating
clearance times of resistant strains with potent inhibitors
Ankit Mahadevia, MD, President & CEO, Spero Therapeutics
10.30 Morning Coffee
10.50 Antibiotic resurrection: Taking the path of least resistance
•Achieving antibiotic sensitivity and resistance prevention
•Nemesis Symbiotics: Delivery options for companion
therapeutics
•Clinical applications
Conrad Lichtenstein, Chief Scientific Officer,
Nemesis Bioscience Ltd
11.30 Building a pipeline and framework for developing novel anti-
microbial drugs
•Are there opportunities beyond small molecule antibiotics?
•Building partnerships and collaborations to drive innovation
•Challenges
•Economics: The elephant in the room?
David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
12.10 Networking Lunch
1.10 Clinical development of broad-spectrum anti-infective
treatment drugs
•Protecting the human microbiome – what do we know?
New frontiers microbiome profiling
•Narrow spectrum vs broad-spectrum antibiotics on the
microbiome
•Pre-clinical to clinical trial evaluation
Jean de Gunzburg, Chief Scientific Officer, Da Volterra
1.50 Determining preclinical PK/PD relationships for faster and
accurate drug development
•Efficiently modelling PK and PD for optimising dosage
requirements of new and existing drugs
•Regulatory recommendations of PK/PD relationships for
antibacterial agents
•Preclinical models of PK/PD results and human translatability
•Individualised treatment and controlling extreme variability
William Hope, Professor, Antimicrobial Pharmacodynamics
and Therapeutics, University of Liverpool
Smart Antimicrobials and Pioneering Approaches
2.30 Antimicrobial peptides as viable alternatives
•Pros and Cons of antimicrobial peptides
•Current pipeline
•Cantab Anti-infectives experience with lantibiotics and
polymyxins.
Steven Boakes, Associate Director of Microbiology,
Cantab Anti-Infectives
3.10 Afternoon Tea
3.30 The use of combination antibiotic therapy
•History of antibiotic combinations
•Rationale for combination therapy
•Advantages / disadvantage of combining antibiotics
•Testing regimens for combination therapy
William Weiss, Director, Pre-Clinical Services,
UNT Health Science Center
4.10 Hyperbaric oxygen treatment as an adjunctive treatment to
infectious diseases and its synergistic effects
•Mechanisms of HBO2 therapy in underpinning improved
immunity and increased antibiotic activity
•A retrospective analysis of patients who received HBO
treatment and outcomes
•Synergistic effects to improve clinical outcomes in patients
post-surgery
Ole Hyldegaard, Medical Director, Associate Professor,
University Hospital of Copenhagen-Rigshospitalet
4.50 Microbiota host interactions as a starting point for
antimicrobial strategies
•Experimental microbiota platforms
•Next generation sequencing
•Analysing AMR development through metagenomics
•Host pathogen/microbiome interactions
Frank Schuren, Senior Scientist Microbiology, TNO
5.20 Chairman’s Closing Remarks and Close of Day Two
2 or call +44 (0)870 9090 711

5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion
specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Supported by
Official Media Partners Official Publications
2015 Attendee Profile by Job Function
Superbugs and Superdrugs
CEO, VP, 22%
Senior management 38%
Director 23%
Academia 17%
2015 Attendee Profile by Sector
Pharma 55%
Regulatory 15%
Vendor 15%
Academia 7%
Consultancy 8%
SMi Pharmaceutical 2016 Planner:
JANUARY
Pharmaceutical Microbiology
20th - 21st January 2016
Holiday Inn Kensington Forum,
London, UK
Social Media In The
Pharmaceutical Industry
20th - 21st January 2016
Holiday Inn Kensington Forum,
London, UK
Pre-Filled Syringes
27th - 28th January 2016
Copthorne Tara Hotel,
London, UK
FEBRUARY
Parallel Trade
8th - 9th February 2016
Holiday Inn Kensington Forum,
London, UK
Advances and Progress
in Drug Design
15th - 16th February 2016
Holiday Inn Kensington Forum,
London, UK
RNAi Therapeutics
15th - 16th February 2016
Holiday Inn Kensington Forum,
London, UK
MARCH
Superbugs & Superdrugs
- A Focus on Antibacterials
16th - 17th March 2016
Holiday Inn Kensington Forum,
London, UK
Paediatric Clinical Trials
16th - 17th March 2016
Holiday Inn Kensington Forum,
London, UK
APRIL
Asthma & COPD
11th - 12th April 2016
Holiday Inn Kensington Forum,
London, UK
Controlled Release
18th - 19th April 2016
Holiday Inn Regents Park,
London, UK
Adaptive Designs
18th - 19th April 2016
Holiday Inn Regents Park,
London, UK
Pre Filled Syringes USA
25th - 26th April 2016
Renaissance Woodbridge,
New Jersey, USA
Lyophilisation USA
27th - 28th April 2016
Renaissance Woodbridge,
New Jersey, USA
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email: tarri@smi-online.co.uk

6. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
SUPERBUGS & SUPERDRUGS
Conference: Wednesday 16th & Thursday 17th March 2016, Holiday Inn Kensington Forum, London, UK
Workshops: Tuesday 15th March 2016, London, UK
4 WAYS TO REGISTER
www.superbugssuperdrugs.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-163
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 30th November 2015 to receive £400 off the conference price
□ Book by 18th December 2015 to receive £200 off the conference price
□ Book by 29th January 2016 to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-163 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on
Document portal and literature distribution for all UK customers and for those EU Customers
not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop AM □ PM □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 1 Workshop only AM □ PM □ £599.00 + VAT £718.80
□ 2 Workshops £1198.00 + VAT £1437.60
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.